| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
p53 (17p13), deletion by FISH : 1003128
Test CodeMDFCPCP53 or 1003128
Alias/See Also
17p; Tp53
CPT Codes
88271, 88275
Instructions
Bone Marrow aspirate in a green top sodium heparin tube (2-3 mL) or Peripheral Blood in a green top sodium heparin tube (2-10 mL).
Transport Container
Blood or Bone Marrow: Do not centrifuge.
Transport Temperature
Blood or Bone Marrow: Ambient temperature within 24 hours. Specimen can be refrigerated if not transported immediately. Do not freeze. Protect from heat with a cold pack.
Specimen Stability
Blood and Bone Marrow: Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable
Methodology
Fluorescence in situ hybridization (FISH)
Setup Schedule
Monday - Friday
Report Available
Up to 7 days
Limitations
Laboratory test results should always be considered in the context of clinical observations. This test was developed and its performance characteristics determined by med fusion. It has not been cleared or approved by the U.S. Food and Drug Administration
(FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments
of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.
(FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments
of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.
Reference Range
An interpretive report will be provided.
Clinical Significance
Deletion of 17p13 is usually associated with allelic loss of the p53 tumor suppressor gene and a poor prognosis. Deletion of p53 is detected by FISH in about 10% of patients with newly diagnosed multiple myeloma and confer a shorter survival, more aggressive disease, higher prevalence of extramedullary disease (such as plasmacytomas), and hypercalcemia. Allelic loss of the TP53 tumor suppressor gene is also considered to be an independent factor of a poor prognosis in B-cell CLL.
Performing Laboratory
med fusion
